Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 3,069 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Intracranial Vascular Disorders Clear all

Conditions: Giant Cell Arteritis
Interventions: mavrilimumab, placebo, prednisone; Combination Product · Drug
Lead sponsor: Kiniksa Pharmaceuticals, Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Sarasota, Florida • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Stroke
Interventions: Anti-platelets and statin, alteplase, intra arterial intervention; Drug · Procedure
Lead sponsor: Jacobs Neurological Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Fabry Disease
Interventions: migalastat; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke, Hemiplegia, Cerebrovascular Accident (CVA), Hemiparesis
Interventions: Contralaterally Controlled Functional Electrical Stimulation, New rTMS approach, Conventional rTMS approach, Sham rTMS approach; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Intracerebral Hemorrhage
Interventions: CN-105; Drug
Lead sponsor: AegisCN LLC; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Lexington, Kentucky • Durham, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Intracerebral Hemorrhage
Interventions: Intravenous nicardipine hydrochloride; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Spasticity
Interventions: Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo; Drug
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more

Conditions: Aneurysm, Stroke, Vasculitis, Tumor Necrosis Factor-alpha
Interventions: Infliximab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions: Cipherome Lighthouse Pilot; Diagnostic Test
Lead sponsor: Cipherome, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Edinburg, Texas

Conditions: Stroke, Gait, Hemiplegic
Interventions: Exoskeleton mediated gait training, High intensity gait training; Behavioral
Lead sponsor: Alvernia University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Allentown, Pennsylvania

Conditions: Stroke
Interventions: Ankle exoskeleton, Baseline (no ankle exoskeleton); Device · Other
Lead sponsor: Georgia Institute of Technology; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Stroke
Interventions: transcranial random noise stimulation and functional electrical stimulation facilitated task practice; Device
Lead sponsor: Amit Sethi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Carotid Stenosis, Stroke, Carotid Artery Plaque, Transient Ischemic Attack, Cerebrovascular Accident, Carotid Artery Stenosis
Interventions: Carotid Endarterectomy or Stenting; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cerebrovascular Diseases, Ischemic Stroke, Repository
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Plaque, Atherosclerotic, Carotid Artery Plaque, Carotid Stenosis
Interventions: Acoustic Radiation Force Impulse (ARFI) ultrasound; Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Central Nervous System Vasculitis, CNS Vasculitis, CNSV, Vasculitis
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: Rochester, Minnesota • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Stroke, Parkinson's Disease, Muscle Weakness
Interventions: Canine Animal-Assisted Therapy, Standard of Care Physical Therapy; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury
Interventions: Magnetic Levator Prosthesis (MLP); Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 4 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aphasia, Aphasia Following Cerebral Infarction, Aphasia, Acquired, Aphasia, Rehabilitation, Aphasia, Anomic, Aphasia, Broca, Aphasia, Conduction, Aphasia, Expressive, Aphasia Non Fluent, Aphasia, Mixed
Interventions: Semantic Feature Analysis (traditional), Semantic Feature Analysis + Metacognitive Strategy Training; Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Intracerebral Hemorrhage
Interventions: DDAVP injection (desmopressin acetate); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
Interventions: Temozolomide; Drug
Lead sponsor: Adam Burgoyne, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: La Jolla, California • Miami, Florida • Portland, Oregon + 1 more

Conditions: Fabry Disease
Interventions: migalastat HCl 150 mg; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia

Conditions: Stroke Gait Rehabilitation
Interventions: Dry Static Cupping, Placebo cupping, Standard physical therapy treatment; Other
Lead sponsor: Scott Getsoian; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Joliet, Illinois

Conditions: Cerebrovascular Accident
Interventions: Transient deafferentation; Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

KPL-301 for Subjects With Giant Cell Arteritis

Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

rTMS Plus CCFES-mediated Functional Task Practice for Severe Stroke

A Proof of Concept Study to Evaluate CN-105 in ICH Patients

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

Comparing Effects of Conventional Neurorehabilitation With Exoskeleton With High-intensity Gait Training

Ankle Exoskeleton for Stroke Gait Enhancement

t-RNS After Hand Recovery in Chronic Stroke

Structural Stability of Carotid Plaque and Symptomatology

Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders

Transcutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk

Longitudinal Study for Central Nervous System Vasculitis

Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs

Clinical Trial to Improve the Magnetic Levator Prosthesis

Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST)

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

The Effect of Cupping on Spasticity and Function of the Lower Extremity During Rehabilitation After Stroke

Ischemic Nerve Block to Improve Hand Function in Stroke Patients